Horizon Pharma, Inc. (NASDAQ:HZNP) announced that Todd N. Smith, executive vice president, chief commercial officer, will present in a fireside chat format discussion at the JMP Securities Healthcare Conference 2014 on Tuesday, June 24, 2014 at 11:30 a.m. Eastern Time in New York, NY. Mr. Smith will provide an overview of the Company and its corporate activities. Horizon Pharma Inc (NASDAQ:HZNP) weekly performance is 5.32%. On last trading day company shares ended up $15.83. Analysts mean target price for the company is $23.67. Horizon Pharma Inc (NASDAQ:HZNP) distance from 50-day simple moving average (SMA50) is 14.02%.
On June 16, 2014 — Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced that the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) has found the effectiveness and safety technical sections complete to support conditional approval under a New Animal Drug Application (NADA) for Karyopharm’s novel, oral Selective Inhibitor of Nuclear Transport (SINE) compound Verdinexor (KPT-335) for the treatment of canine lymphoma. Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares advanced 8.52% in last trading session and ended the day on $44.73. Its return on assets is -49.90%. Karyopharm Therapeutics Inc (NASDAQ:KPTI) quarterly performance is 4.93%.
Stock analysts at William Blair started coverage on shares of Agile Therapeutics Inc (NASDAQ:AGRX) in a report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock. Agile Therapeutics Inc (NASDAQ:AGRX) shares moved up 9.00% in last trading session and was closed at $7.39, while trading in range of $6.90 – $7.84. Agile Therapeutics Inc (NASDAQ:AGRX) year to date (YTD) performance is 33.39%.
On May 28, 2014 –Galectin Therapeutics Inc. (NASDAQ:GALT) the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for patent application number 13/998,197 titled “Galactose-Pronged Carbohydrate Compounds for the Treatment of Diabetic Nephropathy and Associated Disorders.” Galectin Therapeutics Inc. (NASDAQ:GALT) ended the last trading day at $14.75. Company weekly volatility is calculated as 5.31% and price to cash ratio as 8.83. Galectin Therapeutics Inc. (NASDAQ:GALT) showed a positive weekly performance of 5.28%.
Leave a Reply